WO2007103670A3 - Novel compounds that are useful for improving pharmacokinetics - Google Patents
Novel compounds that are useful for improving pharmacokinetics Download PDFInfo
- Publication number
- WO2007103670A3 WO2007103670A3 PCT/US2007/062906 US2007062906W WO2007103670A3 WO 2007103670 A3 WO2007103670 A3 WO 2007103670A3 US 2007062906 W US2007062906 W US 2007062906W WO 2007103670 A3 WO2007103670 A3 WO 2007103670A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- novel compounds
- useful
- improving pharmacokinetics
- pharmacokinetics
- improving
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07757576A EP1993820A4 (en) | 2006-03-02 | 2007-02-27 | Novel compounds that are useful for improving pharmacokinetics |
JP2008557470A JP2009528378A (en) | 2006-03-02 | 2007-02-27 | New compounds useful in improving pharmacokinetics |
CA002643988A CA2643988A1 (en) | 2006-03-02 | 2007-02-27 | Novel compounds that are useful for improving pharmacokinetics |
MX2008011222A MX2008011222A (en) | 2006-03-02 | 2007-02-27 | Novel compounds that are useful for improving pharmacokinetics. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/366,172 | 2006-03-02 | ||
US11/366,172 US7786153B2 (en) | 2005-03-02 | 2006-03-02 | Compounds that are useful for improving pharmacokinetics |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007103670A2 WO2007103670A2 (en) | 2007-09-13 |
WO2007103670A3 true WO2007103670A3 (en) | 2007-11-29 |
Family
ID=38475654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/062906 WO2007103670A2 (en) | 2006-03-02 | 2007-02-27 | Novel compounds that are useful for improving pharmacokinetics |
Country Status (7)
Country | Link |
---|---|
US (4) | US7786153B2 (en) |
EP (1) | EP1993820A4 (en) |
JP (1) | JP2009528378A (en) |
CN (1) | CN101432129A (en) |
CA (1) | CA2643988A1 (en) |
MX (1) | MX2008011222A (en) |
WO (1) | WO2007103670A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9139541B2 (en) | 2006-07-07 | 2015-09-22 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
EP2465856A3 (en) * | 2006-08-31 | 2012-12-12 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
PL3150586T3 (en) | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
AU2008275744A1 (en) * | 2007-07-06 | 2009-01-15 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
JP5629585B2 (en) * | 2008-01-04 | 2014-11-19 | ギリアード サイエンシーズ, インコーポレイテッド | Inhibitor of cytochrome P450 |
US8436005B2 (en) * | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
UA108738C2 (en) * | 2009-04-03 | 2015-06-10 | METHOD OF PREPARATION OF CYTOCHROME INVENTOR P450 MONOOXYGENASES AND INTERMEDIATED INTERMEDIATES | |
KR102334260B1 (en) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 and alk2 inhibitors and methods for their use |
CA2984696C (en) * | 2015-05-04 | 2024-02-06 | Bayer Animal Health Gmbh | Process for the preparation of amphiphilic imidazolinium compounds |
CN112399860A (en) | 2018-06-06 | 2021-02-23 | 麻省理工学院 | Circular RNA for translation in eukaryotic cells |
KR20210038906A (en) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | Methods of treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use therein |
KR20220027855A (en) | 2019-05-22 | 2022-03-08 | 매사추세츠 인스티튜트 오브 테크놀로지 | Circular RNA compositions and methods |
CA3160739A1 (en) | 2019-12-04 | 2021-06-10 | Brian Goodman | Circular rna compositions and methods |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6017928A (en) * | 1992-12-29 | 2000-01-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US20040039029A1 (en) * | 2000-08-15 | 2004-02-26 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
US6703403B2 (en) * | 1995-06-29 | 2004-03-09 | Abbott Laboratories | Method for improving pharmacokinetics |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5610168A (en) * | 1979-07-05 | 1981-02-02 | Chugai Pharmaceut Co Ltd | Pyridine carboxylic acid amide derivative and its production |
IE913840A1 (en) | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
JPH0841006A (en) * | 1994-08-05 | 1996-02-13 | Nisshin Flour Milling Co Ltd | Diurea derivative |
AU1904599A (en) | 1997-12-08 | 1999-06-28 | Scripps Research Institute, The | Hiv/fiv protease inhibitors having a small p3 residue |
GB0002059D0 (en) * | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
US20050131017A1 (en) | 2003-12-11 | 2005-06-16 | Degoey David A. | HIV protease inhibiting compounds |
CA2549228C (en) | 2003-12-11 | 2013-03-19 | Abbott Laboratories | Hiv protease inhibiting compounds |
CN1247554C (en) | 2003-12-24 | 2006-03-29 | 厦门大学 | Process for synthesizing ritonavir |
JP2005274923A (en) * | 2004-03-24 | 2005-10-06 | Fuji Photo Film Co Ltd | Photosensitive resin composition and acridone oligomer |
EP1814548A1 (en) | 2004-11-19 | 2007-08-08 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and reverset |
US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
RS54237B9 (en) | 2006-07-07 | 2019-07-31 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
EP2465856A3 (en) | 2006-08-31 | 2012-12-12 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
-
2006
- 2006-03-02 US US11/366,172 patent/US7786153B2/en not_active Expired - Fee Related
-
2007
- 2007-02-27 MX MX2008011222A patent/MX2008011222A/en active IP Right Grant
- 2007-02-27 CA CA002643988A patent/CA2643988A1/en not_active Abandoned
- 2007-02-27 WO PCT/US2007/062906 patent/WO2007103670A2/en active Application Filing
- 2007-02-27 EP EP07757576A patent/EP1993820A4/en not_active Withdrawn
- 2007-02-27 CN CNA2007800151103A patent/CN101432129A/en active Pending
- 2007-02-27 JP JP2008557470A patent/JP2009528378A/en active Pending
-
2010
- 2010-07-12 US US12/834,315 patent/US8133892B2/en not_active Expired - Fee Related
-
2012
- 2012-01-31 US US13/362,833 patent/US8524753B2/en not_active Expired - Fee Related
-
2013
- 2013-07-30 US US13/954,100 patent/US8741938B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6017928A (en) * | 1992-12-29 | 2000-01-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6703403B2 (en) * | 1995-06-29 | 2004-03-09 | Abbott Laboratories | Method for improving pharmacokinetics |
US20040039029A1 (en) * | 2000-08-15 | 2004-02-26 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9139541B2 (en) | 2006-07-07 | 2015-09-22 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
Also Published As
Publication number | Publication date |
---|---|
US20060199851A1 (en) | 2006-09-07 |
EP1993820A4 (en) | 2009-04-15 |
US8133892B2 (en) | 2012-03-13 |
US8741938B2 (en) | 2014-06-03 |
US8524753B2 (en) | 2013-09-03 |
CA2643988A1 (en) | 2007-09-13 |
US20130317071A1 (en) | 2013-11-28 |
EP1993820A2 (en) | 2008-11-26 |
US7786153B2 (en) | 2010-08-31 |
WO2007103670A2 (en) | 2007-09-13 |
US20100280248A1 (en) | 2010-11-04 |
MX2008011222A (en) | 2008-11-14 |
JP2009528378A (en) | 2009-08-06 |
CN101432129A (en) | 2009-05-13 |
US20120184559A1 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007103670A3 (en) | Novel compounds that are useful for improving pharmacokinetics | |
WO2008027932A3 (en) | Cytochrome p450 oxidase inhibitors and uses thereof | |
WO2009135179A3 (en) | The use of solid carrier particles to improve the processability of a pharmaceutical agent | |
WO2010115000A3 (en) | Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved | |
WO2006105127A3 (en) | Hydroxysteroid dehydrogenase inhibitors | |
WO2009001060A3 (en) | Use of compounds for preparing anti-tuberculosis agents | |
WO2006066109A3 (en) | Hydroxysteroid dehydrogenase inhibitors | |
WO2007061923A3 (en) | Glucokinase activators | |
WO2007028135A3 (en) | Imidazopyridine compounds | |
WO2007087395A3 (en) | UNSATURATED mTOR INHIBITORS | |
IL196490A0 (en) | Pyrazole derivatives as cytochrome p450 inhibitors | |
WO2005074603A3 (en) | Aminobenzoxazoles as therapeutic agents | |
WO2007075847A3 (en) | Glucokinase activators | |
WO2008094222A3 (en) | Porphyrin catalysts and methods of use thereof | |
WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
WO2007133352A3 (en) | Macrocyclic kinase inhibitors | |
WO2011113798A3 (en) | Inhibitors of semicarabazide - sensitive amine oxidase | |
WO2008055236A3 (en) | Mapk/erk kinase inhibitors | |
IL197103A0 (en) | Compositions for inhibiting cytochrome p450 | |
IL172812A0 (en) | Naphthylene derivatives as cytochrome p450 inhibitors | |
WO2009051223A1 (en) | Pharmaceutical composition for treatment of cataract | |
WO2007112913A3 (en) | Benzimidazole derivatives | |
WO2007103934A3 (en) | Compositions and methods of use of ritonavir for treating hcv | |
WO2008153129A1 (en) | Agent for lowering uric acid level | |
WO2006078984A3 (en) | Uses of methylphenidate derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2643988 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008557470 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/011222 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007757576 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780015110.3 Country of ref document: CN |